# European specialty manufacturers H1 2026 earnings

> Live situation record from CLSTR: https://clstr.news/situations/european-specialty-manufacturers-h1-2026-earnings
> Updated: 2026-08-04T19:13:16.000Z. Sources: 16. Developments: 2.

In late July 2026, Swiss peptide maker Bachem reported a modest 4.3 % rise in first‑half sales to CHF 326.4 million, while EBITDA fell 9 % to CHF 82.8 million as the newly opened large‑scale Building K plant increased costs. The company invested CHF 148.4 million in capacity, announced a CHF 350‑400 million capex programme for the year and a further CHF 500 million for its Sisslerfeld site, and set a target of 35‑40 % local‑currency sales growth with EBITDA margins in the low‑thirties by year‑end.

A few days later, German image‑processing specialist Basler AG posted a 36 % jump in first‑half revenue to €152 million and a sharp improvement in EBIT margin to 20.4 %. The firm raised its full‑year revenue outlook to €270‑€290 million and its EBIT‑margin guidance to 12.5‑14.5 %, citing supply‑chain uncertainties. Order intake surged 59 % to €180 million, and the company’s shares rose about 6 % after hours, contributing to a 67 % year‑to‑date gain.

Both companies highlighted strong top‑line growth, but Bachem’s profitability was weighed down by new‑facility ramp‑up costs, whereas Basler’s margins improved and it upgraded its guidance, underscoring divergent financial trajectories within Europe’s specialty manufacturing sector.

## Timeline

### 2026-08-04: Basler lifts revenue and profit outlook after 36% first‑half sales jump

Basler AG raised its 2024 revenue target to €270‑€290 million and EBIT margin to 12.5‑14.5 % after a 36 % sales surge and 59 % jump in order intake in H1, sending its stock up 6 % after hours.

4 sources. https://clstr.news/cluster/basler-lifts-revenue-and-profit-outlook-after-36-firsthalf-sales-jump

### 2026-07-30: Bachem posts 4.3% H1 sales rise and launches new large‑scale Swiss facility

Bachem’s H1 2026 sales rose 4.3% to CHF 326.4 m; EBITDA fell 9% to CHF 82.8 m. It invested CHF 148.4 m, plans CHF 350‑400 m capex plus >CHF 500 m for Sisslerfeld, opened Building K, and appointed Boris Corpatax

13 sources. https://clstr.news/cluster/german-specialty-chemical-firms-alzchem-and-bachem-post-profit-growth-in-h1-2026

---
Cite as: European specialty manufacturers H1 2026 earnings. CLSTR, https://clstr.news/situations/european-specialty-manufacturers-h1-2026-earnings